(Q35212744)

7 August 2017

1 reference

title

Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? (English)

1 reference

7 August 2017

1 reference

1

Paolo Puddu

1 reference

7 August 2017

Giovanni M Puddu

2

1 reference

7 August 2017

Antonio Muscari

series ordinal

3

1 reference

7 August 2017

publication date

1 August 2003

1 reference

International Journal of Cardiology

7 August 2017

published in

1 reference

7 August 2017

volume

90

1 reference

7 August 2017

issue

2-3

1 reference

7 August 2017

page(s)

133-140

1 reference

Medical significance of peroxisome proliferator-activated receptors.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptors: nuclear control of metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

1 reference

7 January 2021

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPAR signaling in the control of cardiac energy metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptors in inflammation control

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Transcription-modulating drugs: a new frontier in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

1 reference

7 January 2021

What have we learned about the biology of atherosclerosis? The role of inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Responses of insulin-like growth factor (IGF)-I and IGF-binding proteins to nutritional status in peroxisome proliferator-activated receptor-alpha knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

The PPARalpha-leukotriene B4 pathway to inflammation control.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Antiatherogenic effects of thiazolidinediones?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Potential roles of the peroxisome proliferator-activated receptor-gamma in macrophage biology and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900565-X

7 January 2021

10.1016/S0167-5273(02)00565-X

Identifiers

DOI

1 reference

7 August 2017

1 reference